Bottom line
Is MHIP a good fund? The bottom line
MHIP is an actively managed inflation-protected bond ETF from Milliman.
Its expense ratio is 0.55% — about $55 a year on every $10,000 invested, more expensive than 55% of inflation-protected bond funds we track.
With $994,139 in net assets and 72 holdings, its largest position is Treasury Bill (25.9%) and the top 10 make up 68.4% of the portfolio.
What to watch
- Concentrated: top 10 holdings are 68.4% of assets
- Small fund ($994,139) — small funds are likelier to close
Updated Nov 19, 2026
What MHIP invests in
The Funds investment objective is to seek to generate returns (before Fund fees and expenses) that over time exceed the U.S. healthcare cost inflation.
The Fund seeks to achieve its investment objective by investing in a combination of assets that Milliman Financial Risk Management LLC, the Funds investment adviser ( Milliman ), believes will produce returns (before Fund fees and expenses) that over time exceed the U.S. healthcare cost inflation rate, as explained below. Accordingly, the Fund may be an appropriate investment for investors looking to over time exceed the U.S. healthcare cost inflation rate. The U.S. healthcare cost inflation rate against which the Fund measures its performance is published on the Funds website at www.millimanfunds.com. How Milliman Calculates the U.S. Healthcare Cost Inflation Rate Milliman is a subsidiary of Milliman, Inc. ( MI ), which is one of the worlds largest providers of actuarial and related products and services. MI has consulting practices in healthcare, property and casualty insurance, life…
From the fund's prospectus (filed Apr 17, 2026).
What MHIP costs
On a $10,000 investment, MHIP's 0.55% expense ratio costs about $55 a year. The median inflation-protected bond fund charges 0.52%.
MHIP top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Treasury Bill | 25.92% |
| 2 | BondBloxx Bloomberg Five Year XFIV | 11.49% |
| 3 | State Street SPDR Portfolio S& SPYM | 8.80% |
| 4 | BondBloxx Bloomberg Six Month XHLF | 4.54% |
| 5 | Eli Lilly & Co LLY | 4.34% |
| 6 | UnitedHealth Group Inc UNH | 3.76% |
| 7 | Johnson & Johnson JNJ | 2.66% |
| 8 | Thermo Fisher Scientific Inc TMO | 2.62% |
| 9 | Abbott Laboratories ABT | 2.18% |
| 10 | SPDR Gold Shares | 2.13% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 68.4% of the fund. See all top 25 holdings and asset mix →